Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 0.87 |
| ▸ | ADAM17 | P78536 | 20/20 | 0.87 |
| ▸ | MMP13 | P45452 | 19/20 | 0.87 |
| ▸ | MMP9 | P14780 | 3/20 | 0.79 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.79 |
| ▸ | MMP3 | P08254 | 2/20 | 0.79 |
| ▸ | ADAM9 | Q13443 | 2/20 | 0.79 |
| ▸ | MMP2 | P08253 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3945436 | 0.93 | MMP1 (1.00) | MMP1ADAM17MMP13MMP9ADAM10 | |
| SCHEMBL3939773 | 0.92 | MMP1 (1.00) | MMP1ADAM17MMP13MMP9ADAM10 | |
| SCHEMBL3942613 | 0.92 | MMP1 (1.00) | MMP1ADAM17MMP13MMP9ADAM10 | |
| SCHEMBL3941937 | 0.92 | MMP1 (1.00) | MMP1ADAM17MMP13MMP9ADAM10 | |
| SCHEMBL7440409 | 0.92 | MMP1 (1.00) | MMP1ADAM17MMP13MMP9ADAM10 | |
| SCHEMBL3948323 | 0.91 | MMP1 (1.00) | MMP1ADAM17MMP13MMP9ADAM10 | |
| SCHEMBL3944800 | 0.91 | MMP1 (1.00) | MMP1ADAM17MMP13MMP9ADAM10 | |
| SCHEMBL3947969 | 0.90 | MMP1 (0.84) | MMP1ADAM17MMP13MMP9ADAM10 | |
| SCHEMBL3948315 | 0.90 | MMP1 (1.00) | MMP1ADAM17MMP13MMP9ADAM10 | |
| SCHEMBL6498529 | 0.90 | MMP1 (1.00) | MMP1ADAM17MMP13MMP9ADAM10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002083112-A2 | METHOD FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH HOLDINGS CORPORATION (US) | 2002-10-24 | — | — | WO | disclosed |